EADO - European Association of Dermato-Oncology

Startseite
Schweiz
Zürich
EADO - European Association of Dermato-Oncology

The EADO is a non-profit association dedicated to promote, coordinate and improve clinical and labor

07/11/2025

In this conversation, Prof. Dr. Josep Malvehy, President of the EADO and Director at Hospital Clínic Barcelona, shares his perspective on how AI technologies are reshaping dermatology and skin cancer care.

🧠 “AI doesn’t replace your knowledge — it complements it.”
From 2D and 3D total body imaging to advanced analytics and natural language tools, AI is becoming a valuable ally for clinicians, supporting diagnostics, research, and patient management.

💡 As Prof. Malvehy highlights, understanding how to interpret and apply AI-generated insights is key: knowing when it helps — and when it doesn’t — will define the next generation of clinical excellence.

📍Follow for Part 2 to explore how AI and real-world data are shaping the future of dermato-oncology.

22/09/2025

🌍 We are proud to announce that the European Association of Dermato-Oncology (EADO) is now an official Member of the International League of Dermatological Societies (ILDS)!

A membership in the International League of Dermatological Societies can significantly enhance the European Association of Dermato-Oncology’s global network, foster collaboration with leading dermatology experts, and strengthen its influence in advancing the field of dermato-oncology worldwide.

This marks an exciting step forward in our mission to connect, educate, and support specialists dedicated to skin cancer and complex skin diseases—on a truly global scale.

🤝 We look forward to contributing actively to the ILDS community and shaping the future of dermatology together.

19/09/2025

🧬 Mitochondrial mutations and melanoma: a new layer of response prediction?
At , Prof. Dr. Payam Gammage, mitochondrial biologist and group leader at the CRUK Scotland Institute (Glasgow), presented emerging data on the role of mitochondrial DNA mutations in shaping tumor metabolism, immune activity, and—critically—response to immunotherapy.

📊 His lab has shown that:
– ~50% of melanomas harbor mitochondrial mutations
– These mutations significantly impact the tumor microenvironment
– Patients whose tumors carry mitochondrial DNA mutations may be 2.5× more likely to respond to checkpoint inhibitors

Despite their frequency, mitochondrial mutations remain underexplored in cancer biology—and Prof. Gammage calls for increased attention within the melanoma research community.

🧪 More data to come—see you in Prague for the 22nd EADO Congress 2026.

04/09/2025

At , Dr. Piotr Wojcieszek, radiation oncologist at the National Research Institute of Oncology in Gliwice (Poland), highlighted the role of interventional radiotherapy (brachytherapy) in the treatment of skin cancers.
📍Key points:
– Brachytherapy is used for a wide range of skin cancers, including non-melanoma, and in selected cases, melanoma, sarcoma, or cutaneous lymphomas
– Techniques include surface and interstitial approaches
– Local control can be excellent when delivered by experienced teams
🩺 His core message: radiation oncologists and brachytherapy specialists should be active contributors in multidisciplinary tumor boards, especially when exploring non-surgical strategies.
📆 See you at the 22nd EADO Congress 2026 in Prague—and don’t forget to call your brachytherapy guys.

28/08/2025

At , Dr. Javier de la Iglesia () from Hospital Clínic Barcelona () presented on pseudomyogenic hemangioendothelioma, a rare vascular tumor most commonly seen in young males, especially in the extremities, though it can also appear in other body regions.
🔬 Diagnosis relies on histopathology and immunohistochemistry, with the tumor typically showing:
✔️ Positive: AE1/AE3, ERG, CD31, FLI1
❌ Negative: S100, desmin, CD34

The tumor is low-grade malignant, often locally recurrent, but with low metastatic potential.

🛠️ Mohs surgery is the main treatment, often requiring multiple stages. In systemic cases, mTOR inhibitors such as sirolimus or tacrolimus may be considered.

📍Stay tuned for more insights and register now for the 22nd EADO Meeting 2026 in Prague [LINK IN BIO] 👈

11/08/2025

🧫 Adoptive cell therapy for metastatic melanoma: where do we go from here?
At the World Congress of Melanoma 2025, Prof. Dr. Gal Markel, Director of the Davidoff Comprehensive Cancer Center (Israel), shared key insights into the next steps for improving TIL therapy (tumor-infiltrating lymphocytes), recently approved for the treatment of metastatic melanoma.

He outlined 3 priority areas to enhance efficacy, safety, and accessibility:
1️⃣ Safety – Optimizing preparatory chemotherapy and IL-2 regimens to expand implementation across more centers and patient populations.
2️⃣ Product improvement – Leveraging epitope targeting, gene editing, and epigenetic reprogramming to develop more selective and potent TILs.
3️⃣ Manufacturing – Using advanced tech to reduce production costs and make treatment more accessible worldwide.

🧪 With multiple phase I trials and biotech investment ongoing, this is a field to watch closely.

07/08/2025

From April 23–25, 2026, we’ll meet at the O₂ Universum () in Prague, Czech Republic — one of Europe’s most modern and accessible congress centres.

Located just 10 minutes from the city centre and 30 minutes from the international airport, O₂ Universum offers cutting-edge facilities, excellent transport connections, and the capacity to host thousands of participants in a dynamic and inspiring setting.

Join us in one of Europe’s most beautiful cities for a congress experience designed for science, networking, and innovation.

🔗 Visit the Congress website at the LINK IN BIO for more details 👀

30/07/2025

🗣️ “Inoperable doesn’t mean incurable.”
At the World Congress of Melanoma 2025 in Athens, Prof. Dr. Petr Arenberger, Chair of Dermatology at Charles University in Prague, delivered a lecture on dermatosurgery—highlighting the therapeutic options available when conventional surgery or radiotherapy is no longer feasible.

🛠️ From new treatment strategies for advanced skin tumors to expanding the definition of what’s treatable, his session emphasized the broadening scope of care in complex dermato-oncological cases.

As a member of the Scientific Programming Committee, Prof. Arenberger also gave a glimpse into the planning for 22nd EADO Congress 2026 in Prague, where themes like empowering the next generation of melanoma specialists will take center stage.

📍We’re just getting started—see you in Prague next year.

Adresse

Max-Högger-Strasse 6
Zürich
8048

Webseite

http://www.eado.org/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von EADO - European Association of Dermato-Oncology erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.